Highlights Redwood Pharma AB

Equities

REDW

SE0021512134

Delayed Nasdaq Stockholm Other stock markets 10:55:04 2024-06-20 EDT			5-day change	1st Jan Change
3.01 ^SEK	-13.26%		+262.65%	-35.96%

06-12	Redwood Pharma Provides an Update on the Process for Divesting the Company's Assets	CI
05-23	Redwood Pharma Provides Update on Process to Divest Assets	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	05-08	CI
Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	05-07	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-15	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-23	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Redwood Pharma AB Presents Positive Results from Clinical Study with RP501 Against Dry Eye	23-05-31	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Redwood Pharma AB Completes Recruitment for Clinical Trial with RP501 for Dry Eye	23-03-17	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Redwood Pharma AB Completes Further Preparations for the Scale-Up of Production of the Company's Medical Technology Product RP501	23-01-24	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Redwood Pharma AB Announces First Patient Has Started Redwood Pharma's Rp501 Treatment for Dry Eye	22-05-05	CI
Redwood Pharma Receives Approval from Austrian Federal Office for Safety in Health Care to Initiate Clinical Trial of RP501	22-03-28	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-16	CI
Redwood Pharma Receives Approval from an Austrian Ethics Committee for Start of A Clinical Trial of RP501	22-02-07	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-16	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Redwood Pharma AB

Equities

REDW

SE0021512134

Highlights

Filters